These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26670976)

  • 21. Pioglitazone for diabetes prevention.
    Goldstein MR; Mascitelli L
    N Engl J Med; 2011 Jul; 365(2):183; author reply 183-4. PubMed ID: 21751925
    [No Abstract]   [Full Text] [Related]  

  • 22. The cage in search of a bird.
    Kalra S
    J Assoc Physicians India; 2012 Jan; 60():74-5. PubMed ID: 22715551
    [No Abstract]   [Full Text] [Related]  

  • 23. PROactive study.
    Goldstein MR
    Lancet; 2006 Jan; 367(9504):23; author reply 26-7. PubMed ID: 16399141
    [No Abstract]   [Full Text] [Related]  

  • 24. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
    Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pioglitazone and the risk of bladder cancer].
    Kado T; Usui I; Tobe K
    Nihon Rinsho; 2016 Apr; 74 Suppl 2():442-6. PubMed ID: 27266132
    [No Abstract]   [Full Text] [Related]  

  • 26. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
    Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
    Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
    Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
    Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
    Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
    BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone: No Longer a Worry for Bladder Cancer?
    Chedgy EC; Black PC
    Urology; 2016 May; 91():19-20. PubMed ID: 26892646
    [No Abstract]   [Full Text] [Related]  

  • 31. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
    Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
    Cagiltay E; Tuncel T; Yönem A; Ozdemir G
    Eur J Intern Med; 2013 Mar; 24(2):e21-2. PubMed ID: 23267737
    [No Abstract]   [Full Text] [Related]  

  • 33. Pioglitazone use and risk of bladder cancer: population based cohort study.
    Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
    BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between pioglitazone and urothelial bladder cancer.
    Barbalat Y; Dombrovskiy VY; Weiss RE
    Urology; 2012 Jul; 80(1):1-4. PubMed ID: 22626574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pioglitazone and bladder cancer: a propensity score matched cohort study.
    Wei L; MacDonald TM; Mackenzie IS
    Br J Clin Pharmacol; 2013 Jan; 75(1):254-9. PubMed ID: 22574756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Observational follow-up of the PROactive study: a 6-year update.
    Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
    Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer.
    Yang X; Chan JC
    Diabetes Care; 2011 Aug; 34(8):e136; author reply 137. PubMed ID: 21788639
    [No Abstract]   [Full Text] [Related]  

  • 40. Selecting the right drug treatment for adults with type 2 diabetes.
    Montori VM
    BMJ; 2016 Mar; 352():i1663. PubMed ID: 27029501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.